Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer

Daisuke Aoki, Yoh Watanabe, Toshiko Jobo, Kimio Ushijima, Kiyoshi Hasegawa, Nobuyuki Susumu, Nao Suzuki, Rui Aoki, Seiji Isonishi, Satoru Sagae, Bunpei Ishizuka, Toshiharu Kamura, Yasuhiro Udagawa, Hiroshi Hoshiai, Yasuo Ohashi, Kazunori Ochiai, Kiichiro Noda

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Background: The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer. Patients and Methods: Women with surgically resected stage Ic-IV epithelial ovarian cancer were treated with docetaxel 70 mg/m2 and cisplatin 60 mg/m2 every 4 weeks. Results: Ninety women were enrolled of whom 89 (median age, 54 years) received a median of 6 cycles (range 1 to 9). With a median 38 months' follow-up, median progression-free survival was 28 months (95% lower confidence interval, 24 months) in 60 patients with stage III-IV disease. The overall response rate for 20 patients was 45%. Neutropenia was the most common (67% ) grade 3/4 toxicity. Major grade 3/4 nonhaematological toxicities were gastrointestinal toxicities (≤11%) and fatigue (8%). No grade 3/4 neurotoxicity was observed. Conclusion: The combination of docetaxel/cisplatin is a regimen with favourable progression-free survival for ovarian cancer.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalAnticancer research
Issue number2
Publication statusPublished - 2009 Feb


  • Cisplatin
  • Clinical trial
  • Docetaxel
  • Ovarian cancer
  • Progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this